Résumé
Objective To investigte the correlation between HLX expression level and AML's clinical variables and different risk stratification.Methods A rcal-time quantitative PCR was used to detect HLX expression in the bone marrow mononuclear cells of 32 de novo AML patients with initial treatment.The relationship between HLX expression level and clinical parameters (FAB classification,hemogram,bone marrow progenitor cells,differentiation and different risk stratification) was investigted.Results The HLX expression of patients with AML was significantly decreased in AML-M3 (P ＜ 0.01),and increased in AML-M5 (P ＜ 0.05).It was negatively correlated with bone marrow progenitor cells (P ＜ 0.01),and was positively correlated with the number of peripheral blood platelet (P ＜0.05).The expression of HLX in AML-M3 was positively correlated with peripheral blood leukocyte levels (P ＜ 0.05),and it was negatively correlated with leukocyte cell level in peripheral blood in AML-M5 (P ＜ 0.05).In AML-Ms groups,the expression levels of HLX of poorly differentiated group were significantly higher than those of the well-differentiated groups (P ＜ 0.05).In AML patients with initial treatment in patient group and non-M3 group,there was no significant difference between the low-risk group and the central risk group (P ＞0.05).Conclution HLX expression levels were elevated in some subtypes,such as AML-M5.and there were differences in different FAB types.HLX gene is associated with the proliferation,differentiation and maturation of leukemia cells.However there was no evidence that HLX is different in different AML risk stratification,which needs further experimental studies.